Alexion Pharmaceuticals, Inc.

David W. Keiser, will retire from his position as president of Alexion Pharmaceuticals by the end of this year. Mr. Keiser, a co-founder of Alexion, played a central role in the commercial launch of Soliris in the U.S. and Europe, and helped to build a broad platform for continued growth in those and other territories. He was appointed chief operating officer since 1992 and president in 2002. Mr. Keiser will remain on the board of directors through the expiration of his current term in 2009 and will be available for consultation in the future. His responsibilities will be distributed among current members of the senior management team, reporting to Leonard Bell, M.D., the company’s chief executive officer.
   
Mr. Keiser joined the company shortly after it was established in 1992, as executive vice president and chief operating officer. He played a central role in managing the company’s manufacturing and regulatory efforts and established commercial teams in the U.S. and Europe to support the 2007 launch of Soliris.
   
“David is a unique individual and executive and I have enjoyed working with him as Alexion built its global organization. His top-level expertise and broad experience were instrumental in our evolution from the early group of scientists into an international organization that is now able to deliver Soliris to a growing number of patients in a growing number of countries,” said Dr. Bell. “Under David’s leadership, we initiated the development of our world-class teams in the U.S. and Europe, and laid a strong foundation for market entry in Asia and the Pacific, the Middle East and Latin America. We are deeply grateful to his numerous, durable contributions to Alexion, and to the people and processes he has put in place to ensure our ongoing success in coming years.”